Genomewide association for schizophrenia in the CATIE study: results of stage 1

• Published in: Molecular psychiatry Vol. 13; no. 6; pp. 570 - 584
• Main Authors: Sullivan, P F, Lin, D, Tzeng, J-Y, van den Oord, E, Perkins, D, Stroup, T S, Wagner, M, Lee, S, Wright, F A, Zou, F, Liu, W, Downing, A M, Lieberman, J, Close, S L
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.06.2008; Nature Publishing Group
• Subjects: Adult and adolescent clinical studies; Antipsychotic Agents - therapeutic use; Antipsychotics; Behavioral Sciences; Biological and medical sciences; Biological Psychology; Bipolar disorder; Body mass index; Care and treatment; Case-Control Studies; Collaboration; Computational Biology; Diabetes; Diagnosis; DNA - genetics; DNA - isolation & purification; Epidemiology; Genetic Markers; Genetic Variation; Genetics; Genome, Human; Genomes; Genomics; Genotype; Genotype & phenotype; Genotyping; Humans; Identification and classification; immediate-communication; Management; Medical sciences; Medicine; Medicine & Public Health; Mental disorders; Methods; National Institute of Mental Health (U.S.); Neurosciences; Nucleotide sequence; Pharmacotherapy; Pharmacy; Phenotypes; Polymorphism, Single Nucleotide; Psychiatry; Psychology. Psychoanalysis. Psychiatry; Psychopathology. Psychiatry; Psychoses; Psychotropic drugs; Quality control; Research institutes; Risk factors; Schizophrenia; Schizophrenia - drug therapy; Schizophrenia - genetics; Single-nucleotide polymorphism; United States; United States; United States > US; Indianapolis Indiana; CATIE; genomewide association; schizophrenia; Psychosis; Schizophrenia

Little is known for certain about the genetics of schizophrenia. The advent of genomewide association has been widely anticipated as a promising means to identify reproducible DNA sequence variation associated with this important and debilitating disorder. A total of 738 cases with DSM-IV schizophre...